PASADENA, Calif. --(BUSINESS WIRE)--Dec. 21, 2022-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it is scheduled to present on January 9, 2023 , at 11:15 a.m. ET at the 41st Annual J.P. Morgan Healthcare Conference being held in San Francisco .
- Announcement on January 9, 2023 , with Webcast at 8:30 a.m. ET PASADENA, Calif. --(BUSINESS WIRE)--Dec. 21, 2022-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that on January 9, 2023 , at 8:30 a.m. ET , it will present topline data from the SEQUOIA Phase 2 study evaluating
PASADENA, Calif. --(BUSINESS WIRE)--Dec. 20, 2022-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced a $25M milestone payment from Amgen (NASDAQ: AMGN). This milestone was triggered by the first subject enrolled in Amgen’s Phase 3 trial of olpasiran.
PASADENA, Calif. --(BUSINESS WIRE)--Dec. 15, 2022-- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that as an inducement to entering into employment with the Company, on December 9, 2022 , the Compensation Committee of the Company’s Board of Directors approved “inducement” grants to
- Arrowhead Earns $15 million Milestone from Horizon Therapeutics plc PASADENA, Calif. --(BUSINESS WIRE)--Dec. 8, 2022-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that Horizon Therapeutics plc (Nasdaq: HZNP) has enrolled the first subject, earning Arrowhead a $15 million
- Conference Call and Webcast Today, November 28, 2022 at 4:30 p.m. ET PASADENA, Calif. --(BUSINESS WIRE)--Nov. 28, 2022-- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal year ended September 30, 2022 . The company is hosting a conference call today,
PASADENA, Calif. --(BUSINESS WIRE)--Nov. 21, 2022-- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming investor events: Piper Sandler 34 th Annual Healthcare Conference – November 30, 2022 Type: Fireside chat presentation
PASADENA, Calif. --(BUSINESS WIRE)--Nov. 14, 2022-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on November 28, 2022 , at 4:30 p.m. ET to discuss its financial results for the 2022 fiscal year ended September 30, 2022 .
- Olpasiran is an siRNA therapeutic being developed by Amgen to reduce risk of cardiovascular disease - Arrowhead retains rights to $400 million in development, regulatory, and sales milestone payments potentially due from Amgen from the 2016 out licensing agreement PASADENA, Calif.
- ARO-APOC3 decreased triglycerides by 86%, and non-HDL-C by 45% while increasing HDL-C by 99% in patients with severe hypertriglyceridemia - ARO-ANG3 decreased triglycerides by 59%, LDL-C by 32%, and was associated with a relative reduction in liver fat fraction in patients with mixed dyslipidemia